QuidelOrtho Corporation (QDEL) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 6, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 7, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the QDEL SEC filings page.
QuidelOrtho Corporation (QDEL) reported $2.7B in revenue over the twelve months to Jun 28, 2026, down 2.5% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
QuidelOrtho’s profitability has collapsed despite broadly stable sales, while debt now weighs more heavily on a shrinking equity base.
Revenue fell9% from FY2023 to FY2025, but operating margin moved into negative territory. That mismatch indicates the earnings deterioration was not simply a volume problem; the cost structure absorbed far more than the sales decline.
The 2025 net loss was
Leverage rose from 0.5x in FY2023 to 1.3x in FY2025. Equity fell from
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of QuidelOrtho Corporation's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
QuidelOrtho Corporation has an operating margin of -33.7%, meaning the company loses $34 on every $100 of revenue. This results in a profitability score of 7/100. This is up from -70.5% the prior year.
QuidelOrtho Corporation's revenue declined 1.9% year-over-year, from $2.8B to $2.7B. This contraction results in a growth score of 17/100.
QuidelOrtho Corporation has a moderate D/E ratio of 1.29. This balance of debt and equity financing earns a leverage score of 42/100.
QuidelOrtho Corporation's current ratio of 1.50 indicates adequate short-term liquidity, earning a score of 41/100. The company can meet its near-term obligations, though with limited headroom.
While QuidelOrtho Corporation generated $105.2M in operating cash flow, capex of $188.2M consumed most of it, leaving -$83.0M in free cash flow. This results in a low score of 21/100, reflecting heavy capital investment rather than weak cash generation.
QuidelOrtho Corporation posts a -58.9% return on equity (ROE), meaning it loses $59 for every $100 of shareholders' equity. This results in a returns score of 8/100. This is up from -68.8% the prior year.
QuidelOrtho Corporation scores -0.06, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($832.5M) relative to total liabilities ($3.8B). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
QuidelOrtho Corporation passes 6 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
QuidelOrtho Corporation reported a net loss of $1.1B while generating $105.2M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
QuidelOrtho Corporation reported an operating loss of $919.2M against $177.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
QuidelOrtho Corporation generated $630.9M in revenue in Q2 2026. This represents an increase of 2.8% from the same quarter a year earlier. Against the prior quarter it is up 1.8%.
QuidelOrtho Corporation's EBITDA was $94.9M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 234.8% from the same quarter a year earlier. Against the prior quarter it is up 17.0%.
QuidelOrtho Corporation reported -$92.9M in net income in Q2 2026. This represents an increase of 63.6% from the same quarter a year earlier. Against the prior quarter it is down 1.2%.
QuidelOrtho Corporation earned -$1.36 per diluted share (EPS) in Q2 2026. This represents an increase of 63.9% from the same quarter a year earlier. Against the prior quarter it is down 0.7%.
Cash & Balance Sheet
QuidelOrtho Corporation recorded an outflow of $136.1M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 61.4% from the same quarter a year earlier. Against the prior quarter it is down 103.1%.
QuidelOrtho Corporation held $123.4M in cash against $2.5B in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Margins & Returns
QuidelOrtho Corporation's gross margin was 43.3% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 1.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.7 percentage points.
QuidelOrtho Corporation's operating margin was -3.5% in Q2 2026, reflecting core business profitability. This is up 26.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.7 percentage points.
QuidelOrtho Corporation's net profit margin was -14.7% in Q2 2026, showing the share of revenue converted to profit. This is up 26.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.1 percentage points.
QuidelOrtho Corporation's ROE was -5.2% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 3.9 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.3 percentage points.
Capital Allocation
QuidelOrtho Corporation invested $48.7M in research and development in Q2 2026. This represents an increase of 6.6% from the same quarter a year earlier. Against the prior quarter it is up 8.5%.
QuidelOrtho Corporation invested $25.5M in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 32.0% from the same quarter a year earlier. Against the prior quarter it is down 25.0%.
Not reported for Q2 2026.
QDEL Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $630.9M+2.8% | $619.8M-10.5% | $723.6M+2.2% | $699.9M-3.7% | $613.9M-3.6% | $692.8M-2.6% | $707.8M-4.9% | $727.1M+9.3% |
| Cost of Revenue | $358.0M+5.6% | $356.0M+1.9% | $403.2M+5.6% | $364.3M-2.8% | $339.0M-6.1% | $349.5M-7.8% | $381.7M+1.9% | $374.8M+1.7% |
| Gross Profit | $272.9M-0.7% | $263.8M-23.2% | $320.4M-1.7% | $335.6M-4.7% | $274.9M-0.4% | $343.3M+3.4% | $326.1M-11.7% | $352.3M+18.8% |
| R&D Expenses | $48.7M+6.6% | $44.9M-15.6% | $45.8M-3.2% | $41.5M-25.8% | $45.7M-18.8% | $53.2M-10.1% | $47.3M-23.1% | $55.9M-10.4% |
| SG&A Expenses | $189.7M+6.6% | $199.3M+6.6% | $194.4M+3.7% | $186.9M+0.3% | $178.0M-5.4% | $187.0M-8.6% | $187.5M-3.4% | $186.4M+4.1% |
| Operating Income | -$21.8M+87.9% | -$31.8M-197.5% | -$66.3M+34.0% | -$704.8M-4798.7% | -$180.7M-53.8% | $32.6M+101.9% | -$100.4M-481.7% | $15.0M+155.8% |
| EBITDA | $94.9M+234.8% | $81.1M-41.9% | $46.2M+419.1% | -$592.7M-562.7% | -$70.4M-4928.6% | $139.7M+108.5% | $8.9M-93.6% | $128.1M+46.2% |
| Interest Expense | $54.7M+35.1% | $51.1M+27.8% | $51.0M+25.6% | $46.1M+7.5% | $40.5M-1.2% | $40.0M+2.6% | $40.6M+207.7% | $42.9M+217.5% |
| Income Tax | $11.7M-54.7% | $12.3M+215.4% | $18.3M-51.2% | -$23.9M-168.5% | $25.8M+269.7% | $3.9M+104.2% | $37.5M+1439.3% | -$8.9M+20.5% |
| Net Income | -$92.9M+63.6% | -$91.8M-622.8% | -$130.7M+26.7% | -$733.0M-3583.4% | -$255.4M-72.9% | -$12.7M+99.3% | -$178.4M-1304.7% | -$19.9M+62.6% |
| EPS (Basic) | -$1.36+63.9% | -$1.35-610.5% | -$1.90+27.5% | -$10.78-3493.3% | -$3.77-71.4% | -$0.19+99.3% | -$2.62-1278.9% | -$0.30+62.5% |
| EPS (Diluted) | -$1.36+63.9% | -$1.35-610.5% | -$1.90+27.5% | -$10.78-3493.3% | -$3.77-71.4% | -$0.19+99.3% | -$2.62-1278.9% | -$0.30+62.5% |
| Diluted Shares (Avg) | 68M+0.9% | 68M+1.0% | N/A | 68M+1.0% | 68M+0.9% | 68M+0.9% | N/A | 67M+0.7% |
QDEL Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $5.7B-10.4% | $5.6B-12.9% | $5.8B-10.2% | $5.7B-16.6% | $6.4B-4.6% | $6.5B-3.6% | $6.4B-24.8% | $6.8B-20.5% |
| Current Assets | $1.4B+7.4% | $1.4B+9.4% | $1.4B+18.7% | $1.4B-3.2% | $1.3B-4.5% | $1.3B+3.8% | $1.2B-11.1% | $1.4B+8.0% |
| Cash & Equivalents | $123.4M-18.7% | $140.4M+10.5% | $169.8M+72.7% | $98.1M-31.7% | $151.7M+41.8% | $127.1M+61.9% | $98.3M-34.2% | $143.7M-19.5% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0-100.0% | $0-100.0% |
| Inventory | $618.9M+6.9% | $611.5M+8.6% | $577.6M+8.2% | $613.8M+6.4% | $578.7M-3.9% | $563.2M-3.4% | $533.7M-3.3% | $577.0M+6.4% |
| Accounts Receivable | $352.0M+28.0% | $359.9M+25.8% | $417.0M+47.7% | $386.5M+31.1% | $275.0M+2.0% | $286.0M+5.3% | $282.4M-14.7% | $294.9M+19.5% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0-100.0% | $0-100.0% |
| Goodwill | N/A | N/A | $0-100.0% | $0-100.0% | $711.1M-2.9% | $670.9M-8.7% | $649.5M-73.4% | $770.6M-68.8% |
| Total Liabilities | $3.9B+9.9% | $3.8B+9.0% | $3.8B+11.9% | $3.6B+0.7% | $3.6B+2.0% | $3.5B+2.0% | $3.4B-3.7% | $3.6B+1.9% |
| Current Liabilities | $993.4M-13.0% | $962.4M-8.1% | $966.1M-3.3% | $767.9M-25.3% | $1.1B+22.5% | $1.0B+34.3% | $998.8M+16.1% | $1.0B+30.0% |
| Non-Current Liabilities | $2.9B+20.6% | $2.8B+16.5% | $2.9B+18.1% | $2.9B+11.0% | $2.4B-5.4% | $2.4B-7.6% | $2.4B-10.0% | $2.6B-6.2% |
| Long-Term Debt | $2.5B+22.4% | $2.5B+16.8% | $2.5B+15.4% | $2.5B+14.7% | $2.1B-6.1% | $2.1B-6.0% | $2.1B-13.2% | $2.2B-13.5% |
| Total Equity | $1.8B-36.4% | $1.9B-38.2% | $1.9B-35.7% | $2.0B-36.1% | $2.8B-12.0% | $3.0B-9.4% | $3.0B-39.9% | $3.2B-36.3% |
| Retained Earnings | -$1.2B-792.4% | -$1.1B-983.7% | -$996.0M-833.4% | -$865.3M-375.4% | -$132.3M-139.6% | $123.1M-74.4% | $135.8M-93.8% | $314.2M-85.7% |
QDEL Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$110.6M-136.3% | -$33.0M-150.3% | $131.9M+107.1% | -$45.5M-138.6% | -$46.8M+52.2% | $65.6M+9471.4% | $63.7M+53.5% | $117.9M+485.3% |
| Depreciation & Amortization | $116.7M+5.8% | $112.9M+5.4% | $112.5M+2.9% | $112.1M-0.9% | $110.3M-5.0% | $107.1M-6.8% | $109.3M-3.4% | $113.1M-1.2% |
| Stock-Based Compensation | $12.0M-6.3% | $10.7M-7.8% | N/A | $10.8M-13.6% | $12.8M+14.3% | $11.6M+28.9% | N/A | $12.5M-26.5% |
| Capital Expenditures | $25.5M-32.0% | $34.0M-39.5% | $45.3M-4.0% | $49.2M+5.8% | $37.5M+6.2% | $56.2M-15.0% | $47.2M+8.8% | $46.5M-9.4% |
| Free Cash Flow | -$136.1M-61.4% | -$67.0M-812.8% | $86.6M+424.8% | -$94.7M-232.6% | -$84.3M+36.7% | $9.4M+114.1% | $16.5M+968.4% | $71.4M+187.2% |
| Investing Cash Flow | -$107.3M-225.2% | -$34.0M+39.5% | -$49.6M-30.9% | -$53.9M+4.6% | -$33.0M+6.5% | -$56.2M-178.2% | -$37.9M-77.9% | -$56.5M-33.6% |
| Financing Cash Flow | $200.6M+94.2% | $37.6M+113.6% | -$11.1M+83.9% | $46.0M+274.9% | $103.3M-36.4% | $17.6M+195.1% | -$68.9M-41.5% | -$26.3M+73.6% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
QDEL Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 43.3%-1.5pp | 42.6%-7.0pp | 44.3%-1.8pp | 47.9%-0.5pp | 44.8%+1.4pp | 49.5%+2.8pp | 46.1%-3.6pp | 48.4%+3.9pp |
| Operating Margin | -3.5%+26.0pp | -5.1%-9.8pp | -9.2%+5.0pp | -100.7% | -29.4%-11.0pp | 4.7% | -14.2%-17.7pp | 2.1%+6.1pp |
| Net Margin | -14.7%+26.9pp | -14.8%-13.0pp | -18.1%+7.1pp | -104.7% | -41.6%-18.4pp | -1.8% | -25.2%-23.5pp | -2.7%+5.3pp |
| Return on Equity | -5.2%+3.9pp | -5.0%-4.5pp | -6.8%-0.8pp | -36.0%-35.4pp | -9.2%-4.5pp | -0.4%+51.2pp | -6.0%-5.7pp | -0.6%+0.4pp |
| Return on Assets | -1.6%+2.4pp | -1.6%-1.4pp | -2.3%+0.5pp | -12.9%-12.6pp | -4.0%-1.8pp | -0.2%+25.3pp | -2.8%-2.6pp | -0.3%+0.3pp |
| Current Ratio | 1.39+0.3x | 1.43+0.2x | 1.50+0.3x | 1.78+0.4x | 1.12-0.3x | 1.20-0.4x | 1.22-0.4x | 1.38-0.3x |
| Debt-to-Equity | 1.43+0.7x | 1.33+0.6x | 1.29+0.6x | 1.23+0.5x | 0.740.0x | 0.700.0x | 0.72+0.2x | 0.68+0.2x |
| Asset Turnover | 0.110.0x | 0.110.0x | 0.130.0x | 0.120.0x | 0.100.0x | 0.110.0x | 0.110.0x | 0.110.0x |
| FCF Margin | -21.6%-7.8pp | -10.8%-12.2pp | 12.0%+9.6pp | -13.5%-23.3pp | -13.7%+7.2pp | 1.4%+10.8pp | 2.3%+2.6pp | 9.8%+22.1pp |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| QuidelOrtho Corporation QDEL | FY2025 | $2.7B | -$1.1B | -41.4% | $832.5M | 23/100 |
| PROCEPT BioRobotics Corporation PRCT | FY2025 | $308.1M | -$96K | 0.0% | $982.8M | 54/100 |
| Inspire Medical Systems, Inc. INSP | FY2025 | $912.0M | $145.4M | 16.0% | $2.0B | 64/100 |
| Alphatec Holdings, Inc. ATEC | FY2025 | $764.2M | -$143.4M | -18.8% | $1.5B | 35/100 |
| Haemonetics Corporation HAE | FY2026 | $1.3B | $97K | 0.0% | $4.8B | 58/100 |
| LivaNova PLC LIVN | FY2025 | $1.4B | -$242.5M | -17.5% | $4.1B | 59/100 |
Where QuidelOrtho Corporation Ranks
Frequently Asked Questions
What is QuidelOrtho Corporation's annual revenue?
QuidelOrtho Corporation (QDEL) reported $2.7B in total revenue for fiscal year 2025. This represents a -1.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is QuidelOrtho Corporation's revenue growing?
QuidelOrtho Corporation (QDEL) revenue declined by 1.9% year-over-year, from $2.8B to $2.7B in fiscal year 2025.
Is QuidelOrtho Corporation profitable?
No, QuidelOrtho Corporation (QDEL) reported a net income of -$1.1B in fiscal year 2025, with a net profit margin of -41.4%.
What is QuidelOrtho Corporation's EBITDA?
QuidelOrtho Corporation (QDEL) had EBITDA of -$477.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does QuidelOrtho Corporation have?
As of fiscal year 2025, QuidelOrtho Corporation (QDEL) had $169.8M in cash and equivalents against $2.5B in long-term debt.
What is QuidelOrtho Corporation's gross margin?
QuidelOrtho Corporation (QDEL) had a gross margin of 46.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is QuidelOrtho Corporation's operating margin?
QuidelOrtho Corporation (QDEL) had an operating margin of -33.7% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is QuidelOrtho Corporation's net profit margin?
QuidelOrtho Corporation (QDEL) had a net profit margin of -41.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is QuidelOrtho Corporation's return on equity (ROE)?
QuidelOrtho Corporation (QDEL) has a return on equity of -58.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is QuidelOrtho Corporation's free cash flow?
QuidelOrtho Corporation (QDEL) recorded an outflow of $83.0M in free cash flow during fiscal year 2025. This represents a 26.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is QuidelOrtho Corporation's operating cash flow?
QuidelOrtho Corporation (QDEL) generated $105.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are QuidelOrtho Corporation's total assets?
QuidelOrtho Corporation (QDEL) had $5.8B in total assets as of fiscal year 2025, including both current and long-term assets.
What are QuidelOrtho Corporation's capital expenditures?
QuidelOrtho Corporation (QDEL) invested $188.2M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does QuidelOrtho Corporation spend on research and development?
QuidelOrtho Corporation (QDEL) invested $186.2M in research and development during fiscal year 2025.
What is QuidelOrtho Corporation's current ratio?
QuidelOrtho Corporation (QDEL) had a current ratio of 1.50 as of fiscal year 2025, which is considered adequate.
What is QuidelOrtho Corporation's debt-to-equity ratio?
QuidelOrtho Corporation (QDEL) had a debt-to-equity ratio of 1.29 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is QuidelOrtho Corporation's return on assets (ROA)?
QuidelOrtho Corporation (QDEL) had a return on assets of -19.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is QuidelOrtho Corporation's P/E ratio?
QuidelOrtho Corporation (QDEL) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 28, 2026). The market capitalization is $832.5M as of Oct 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is QuidelOrtho Corporation's price-to-sales ratio?
QuidelOrtho Corporation (QDEL) trades at 0.3x sales, its market capitalization divided by revenue of $2.7B revenue, trailing 12 months to June 28, 2026. The market capitalization is $832.5M as of Oct 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is QuidelOrtho Corporation's Altman Z-Score?
QuidelOrtho Corporation (QDEL) has an Altman Z-Score of -0.06, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is QuidelOrtho Corporation's Piotroski F-Score?
QuidelOrtho Corporation (QDEL) has a Piotroski F-Score of 6 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are QuidelOrtho Corporation's earnings high quality?
QuidelOrtho Corporation (QDEL) reported a net loss of $1.1B while generating $105.2M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can QuidelOrtho Corporation cover its interest payments?
QuidelOrtho Corporation (QDEL) reported an operating loss of $919.2M against $177.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is QuidelOrtho Corporation?
QuidelOrtho Corporation (QDEL) scores 23 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.